Ipilimumab-associated lymphocytic colitis: a case report
Case Report

Ipilimumab-associated lymphocytic colitis: a case report

Paul E. St. Romain, April K. S. Salama, N. Lynn Ferguson, Rebecca A. Burbridge

Duke University Medical Center, USA

Correspondence to: Paul E. St. Romain. Duke University Medical Center, USA. Email: paulstromain@gmail.com.

Abstract: Ipilimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitor approved for treatment of metastatic melanoma. Gastrointestinal side effects are common and include diarrhea, colitis, and hepatitis. Histopathology typically shows active neutrophilic colitis, and microscopic colitis is rare with only one biopsy-proven case reported in the literature. We now report a second case of microscopic colitis associated with treatment with ipilimumab. While treatment of ipilimumab-associated colitis is typically discontinuation of the drug and systemic steroids followed by infliximab if no response to steroids, in our case the patient’s symptoms responded to oral budesonide alone, and therapy with ipilimumab was successfully resumed. The etiology of ipilimumab-associated colitis is unknown but may be related to loss of CTLA-4-expressing T-regulatory cells.

Keywords: Ipilimumab; microscopic; lymphocytic colitis; melanoma metastatic


Submitted Oct 26, 2015. Accepted for publication Oct 27, 2015.

doi: 10.3978/j.issn.2224-4778.2015.10.11


Introduction

Ipilimumab is a fully human monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) approved for treatment of unresectable or metastatic melanoma. Blockade of CTLA-4 increases T-cell activation and proliferation, with the potential to manifest unique side effects, termed immune-related adverse effects (irAEs) including dermatitis, colitis, hypophysitis, thyroiditis, and hepatitis. Immune-related events occur in up to 60% of patients, with diarrhea of any grade in 27–31% of patients and enterocolitis occurring in 7% of patients (1). The recommended management of severe toxicity is discontinuation of the drug and treatment with systemic steroids followed by infliximab if systemic steroids are ineffective; oral budesonide alone has been found to be ineffective for preventing toxicity (2,3). Studies that have assessed the endoscopic and histopathologic findings of ipilimumab-associated gastrointestinal toxicities have generally shown changes characteristic of autoimmune enteropathy or active colitis, with only one case of microscopic colitis previously reported (2,4,5). We report a case of a 54-year-old woman with metastatic melanoma who developed lymphocytic colitis after treatment with ipilimumab, which was successfully treated with oral budesonide.


Case representation

An asymptomatic 54-year-old woman with a history of biopsy-proven, BRAF V600E-positive, metastatic melanoma presented to our institution in December 2014 for further management of her melanoma. Given her excellent performance status and low overall tumor burden, the decision was made to start ipilimumab. She received her first dose of ipilimumab at 3 mg/kg on December 18.

At follow-up for her second cycle on January 12, she endorsed watery stools, abdominal cramping, and tenesmus, all of which had developed one week after her first dose of ipilimumab. Laboratory studies were notable for normal liver chemistries, hemoglobin of 9.9 g/dL, white blood cell count of 7.1×109/L, random cortisol of 8.9 mcg/dL, and thyroid stimulating hormone of 0.72 mcIU/mL. Stool studies were notable for negative fecal leukocytes, negative stool culture, negative exam for ova and parasites, and negative clostridium difficile toxin assay by PCR. A colonoscopy performed January 15 showed normal colonic mucosa and terminal ileum without any evidence of inflammation. Multiple random biopsies were taken from throughout the colon. Pathology results revealed colonic mucosa with intraepithelial lymphocytosis and increased apoptotic activity (Figure 1). There was expansion of the lamina propria by lymphoplasmacytic inflammation and numerous apoptotic bodies with surface epithelial injury and reactive change (Figures 2,3). The findings were thought to suggest lymphocytic colitis although the exuberant apoptosis was unusual in lymphocytic colitis and the differential of drug effect superimposed on typical lymphocytic colitis was suggested. Apart from ipilimumab, she had not started any new medications. Her symptoms had not responded to symptomatic treatment with loperamide and lomotil; on January 23, the patient was started on 9 mg budesonide daily and reported rapid improvement of diarrhea. She was subsequently tapered over 6 weeks and resumed therapy with ipilimumab 4 weeks into her taper. Her diarrhea has not recurred off steroids.

Figure 1 Colonic mucosa with relatively preserved architecture and surface epithelial injury with reactive changes (H&E, 10×).
Figure 2 Expansion of the lamina propria by lymphoplasmacytic inflammation and numerous lymphocytes present within the crypt epithelium (H&E, 20×).
Figure 3 Numerous apoptotic bodies are present within the crypt epithelium (H&E, 20×).

Discussion

Ipilimumab is well known to be associated with gastrointestinal side effects, with diarrhea occurring in almost a third of patients; however, microscopic colitis is an extremely unusual cause of diarrhea in patients receiving ipilimumab (1). Johnston et al. evaluated a patient with ipilimumab-associated diarrhea using flexible sigmoidoscopy and biopsies and found edematous and ulcerated mucosa with histopathology showing acute and chronic inflammation, cryptitis, and crypt abscesses (6). Oble et al. described a series of five patients who developed severe gastrointestinal toxicity of the stomach, small intestine, and colon. Endoscopic findings varied from normal to diffusely erythematous and ulcerated mucosa, and histology showed lymphoplasmacytic expansion of the lamina propria with increased intraepithelial lymphocytes, increased epithelial apoptosis, cryptitis and glandular inflammation, and villous blunting in the ileal and duodenal mucosa, felt to be most consistent with autoimmune enteropathy (4). Berman et al. evaluated the distal colon and rectum of 115 patients in a phase II trial intended to further elucidate the mechanism of ipilimumab-induced gastrointestinal toxicity, and found the most common histopathologic abnormalities to be active colitis with a mixed inflammatory cell infiltrate in the lamina propria and intraepithelial neutrophils and crypt abscesses. However, intraepithelial lymphocytes were not increased. Furthermore, subjects were randomized to treatment with prophylactic concomitant oral budesonide versus placebo, and budesonide was not helpful in preventing symptoms of toxicity or altering histopathologic findings (7).

Although inflammation of the stomach, small intestine, and colon have been described previously in association with ipilimumab, histopathologic findings consistent with lymphocytic colitis are rare. In the only other reported case to date, Garcia-Varona, Odze and Makrauer describe a 65-year-old male with stage IV ocular melanoma who developed watery diarrhea and abdominal discomfort 6 weeks after initiating ipilimumab therapy. Biopsies from the rectum, sigmoid, and descending colon showed normal crypt architecture but with markedly increased intraepithelial lymphocytes and a diffuse lymphoplasmacytic infiltrate with scattered eosinophils in the lamina propria. The patient was treated with oral and systemic steroids, and symptoms resolved in two weeks despite continuation of ipilimumab therapy (5).

The mechanism of ipilimumab-associated gastrointestinal toxicity is unknown. It may result from depletion of mucosal T-regulatory cells that express high levels of CTLA-4 or from formation of bacterial breakdown products that result in increased inflammatory cell recruitment (5).

In conclusion, we describe a rare case of ipilimumab-associated microscopic colitis in a 54-year-old woman with metastatic melanoma in whom diarrhea resolved with local oral steroid therapy alone. Our limited findings and review of the literature suggest that microscopic colitis may be managed with local steroid therapy and that drug discontinuation may not be mandatory, in contrast to the recommended management of ipilimumab-induced enterocolitis. As ipilimumab gains increasing use in the therapy of metastatic melanoma, as well as other malignancies, the recognition and management of various manifestations of gastrointestinal side effects will be of increasing importance in order to appropriately manage potential toxicities.


Acknowledgements

None.


Footnote

Conflicts of Interest: Dr. Salama has served on an advisory board for Bristol-Myers Squibb, and receives research funding through her institution from BMS, Merck, Genentech, Reata, and Celldex. The other authors have no conflicts of interest to declare.

Informed Consent: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.


References

  1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23. [PubMed]
  2. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun 2010;10:11. [PubMed]
  3. Andrews S, Holden R. Characteristics and management of immunerelated adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res 2012;4:299-307. [PubMed]
  4. Oble DA, Mino-Kenudson M, Goldsmith J, et al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol 2008;32:1130-7. [PubMed]
  5. García-Varona A, Odze RD, Makrauer F. Lymphocytic colitis secondary to ipilimumab treatment. Inflamm Bowel Dis 2013;19:E15-6. [PubMed]
  6. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009;54:2538-40. [PubMed]
  7. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15:5591-8. [PubMed]
Cite this article as: St. Romain PE, Salama AK, Ferguson NL, Burbridge RA. Ipilimumab-associated lymphocytic colitis: a case report. Transl Gastrointest Cancer 2016;5(1):44-46. doi: 10.3978/j.issn.2224-4778.2015.10.11

Refbacks

  • There are currently no refbacks.